TERF1 and metabolic dysfunction-associated steatotic liver disease: Furthermore, ferroptosis inhibitors, TRF, and ECH1 which take ferroptosis as target have been confirmed to have great potential in the treatment of NAFLD in many animal studies (26, 126, 130, 149, 150).